Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Avatar Builder  |  Contact Info  |  Update Email  |  Update Password  |  Leaderboards  |  Manage Favourite  |  Reputation  |  Reputation History  |  Subscriptions  |  Payment Info  |  Invoices  |  Favourites

Bullboard Post History

by Noteable

T.ONC

RE:RE:RE:RE:RE:RE:RE:30 million for breast cancer trial

Should read : Quentin30 has admitted he doesn't own shares in ONCY, 

September 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:30 million for breast cancer trial

And now that Quentin30 has admitted he doesn't own she's in ONCY...

September 19, 2024

T.ONC

RE:RE:RE:RE:RE:30 million for breast cancer trial

Kirk Look said nothing about a tineline of 3-5 years. It's all in your...

September 19, 2024

T.ONC

RE:RE:RE:RE:30 million for breast cancer trial

Demand is hot for big results in key markets like mBC with an unmet treatment...

September 19, 2024

T.ONC

RE:RE:RE:30 million for breast cancer trial

Repeatedly having to be restated - ONCY'S  patents do nor run out...

September 19, 2024

T.ONC

RE:30 million for breast cancer trial

ONCY has $500 million in R&D write-offs and the potential of $US 5.89...

September 19, 2024

T.ONC

RE:RE:RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

Demand is hot for big results in key markets like mBC with an unmet treatment...

September 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Learn to read Buckeroo .... I repeated what Kirk Look said last week, which...

September 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

This kind of positive news on long-term results generally results in a deal, ...

September 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Kirk Look's presentation at Cantor's Global Healthcare Conference was...

September 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Somebody from ONCY needs to step up their responsibilites in knocking down...

September 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Another giant step towards pelareorep's potential Accelerated Approval...

September 19, 2024

T.ONC

RE:RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

September 19, 2024 - At the Cantor Fiztgerald Global Healthcare Conference...

September 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Great News on what the FDA considers the primary clinical benefit for an...

September 19, 2024

T.ONC

RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

September 18, 2024 - Post ESMO 2024 Dr. Alessandra Curioni-Fontecedro...

September 18, 2024

T.ONC

RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

Since some have difficulty seeing, I'll repost the following assessment...

September 18, 2024

T.ONC

RE:RE:RE:Quentin30 is a pathological prevaricator.

This email trail header expresses who Quentin30 really is.

September 18, 2024

T.ONC

RE:RE:RE:Market Up...

Well if you see nothing but copying and pasting from me, I would strongly...

September 18, 2024

T.ONC

RE:RE:RE:RE:RE:How does Accelerated Approval work

ONCY is set to run 2 trials in 1 in their planned adaptive designed180-200...

September 18, 2024

T.ONC

RE:RE:RE:RE:How does Accelerated Approval work

September 17, 2024 -  21 USC 356: Expedited approval of drugs for...

September 18, 2024

Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next

Featured Company

Alphamin Resources Corp.

Alphamin Resources Corp. V.AFM

Alphamin Resources Corp. is a Mauritius-based company, which is engaged in the production and sale of tin concentrate from ... view more »